Advertisement

Preventing and Treating Dental Implant Complications from Drugs Known to Cause Osteonecrosis of the Jaws

  • Robert E. MarxEmail author
Chapter
  • 12 Downloads

Abstract

The prevention and management of Drug Induced Osteonecrosis of the Jaws (DIONJ) is different from the osteoporosis patient compared to the metastatic cancer patient.

The drugs at greatest risk for DIONJ in the osteoporosis patients are alendronate and denosumab where as residronate and ibandronate patients are at minimal risk and raloxifene, rhPTH1–34, strontium renelate, and vitamin D3 with calcium pose no risk. In patients on bisphosphonates, a presurgical drug holiday of 9 months followed by a postsurgical drug holiday of 3 months reduces the risk for clinical DIONJ to the lowest possible and is useful when treating the exposed necrotic bone in established DIONJ in this patient group.

The drugs at greatest risk for DIONJ in the metastatic cancer patients are Zoledronate and denosumab. This risk is even higher if Zoledronate was begun and was followed by denosumab. In patients who have received Zoledronate alone or initially received Zoledronate followed by denosumab, implant placement is very risky to develop DIONJ due to the 11.2 year half-life of bisphosphonates. If the patient has received only denosumab its short half-life of 26 days lends itself to implant placement and/or surgical debridement of existing DIONJ using a 4 months drug holiday before the procedure and 3 month drug holiday after the procedure.

Keywords

Drug-induced osteonecrosis Drug holidays Osteoporosis Metastatic cancer 

References

  1. 1.
    Chung PL, Zhou S, Eslami B, Shen L, LeBoff MS, Glowacki J. Effect of age on regulation of human osteoclast differentiation. J Cell Biochem. 2014;115(8):1412–9.CrossRefGoogle Scholar
  2. 2.
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–50.CrossRefGoogle Scholar
  3. 3.
    Lasseter KC, Porras AG, Denker A, Santhanagopal A, Daifotis A. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig. 2005;25(2):107–14.CrossRefGoogle Scholar
  4. 4.
    Marx RE. Oral & intravenous bisphosphonate induced osteonecrosis of the jaws, history, etiology, prevention, and treatment. 2nd ed. Tokyo: Quintessence Publishing Company; 2011.Google Scholar
  5. 5.
    Food and Drug Administration. Background document for meeting of Advisory Committee for reproductive health drug and drug safety and Risk Management Advisory Committee. FDA, September 9, 2011. http://wwwfda.gov/downloads/advisorycommittees/committeesmeetings.
  6. 6.
    Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66(2):100–3.CrossRefGoogle Scholar
  7. 7.
    Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397–410.CrossRefGoogle Scholar
  8. 8.
    Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res. 2011;22(1):100–5.CrossRefGoogle Scholar
  9. 9.
    Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(6):1167–73.CrossRefGoogle Scholar
  10. 10.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.CrossRefGoogle Scholar
  11. 11.
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.CrossRefGoogle Scholar
  12. 12.
    Miglorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, et al. Managing the care of patients with bisphosphonate associated osteonecrosis. An American Academy of Oral Medicine Position Paper. J Am Dent Assoc. 2005;136:1658–68.CrossRefGoogle Scholar
  13. 13.
    Ruggiero SL, Dodson TB, Assael LA, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaws. 2009, update. J Oral Maxillo Surg. 2009;67(5 Suppl):2–12.Google Scholar
  14. 14.
    Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354–8.CrossRefGoogle Scholar
  15. 15.
    Novartis AG. Zometa. Zoledronic acid injection. Produce information sheet. Novartis AG; 2004.Google Scholar
  16. 16.
    Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl). 2001;79(5–6):243–53.CrossRefGoogle Scholar
  17. 17.
    Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–802.CrossRefGoogle Scholar
  18. 18.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Oral and Maxillofacial SurgeryUniversity of Miami Miller School of Medicine/Jackson Health SystemsMiamiUSA

Personalised recommendations